EVO Stock Analysis: Buy, Sell, or Hold?
EVO - Evotec SE American Depositary Shares
$2.14
-0.29 (-11.93%)
▼
5d:
-24.91%
30d:
-21.32%
90d:
-23.02%
WAIT
LOW Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: May 06, 2026
0d
Get Alerted When EVO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: EVO is down 24.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: EVO is down 24.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: EVO is currently trading at $2.14, which is considered oversold relative to its 30-day fair value range of $2.55 to $2.87. From a valuation perspective, the stock is trading at a discount (Forward PE: -13.8) compared to its historical average (45.3). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, EVO is showing sideways momentum. The price is currently testing key support at $2.10. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 11.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.12 (+139.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EVO is showing sideways momentum. The price is currently testing key support at $2.10. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 11.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.12 (+139.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.55 -
$2.87
Company Quality Score
40/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-11.9%)
- BULLISH: Trading 139.1% below Wall St target ($5.12)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Recommendation downgraded due to -24.9% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$2.55 -
$2.87
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.10
Resistance Level
$2.93
Current Trend
Sideways
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-13.81
Wall Street Target
$5.12
(+139.1%)
Revenue Growth (YoY)
-21.7%
Profit Margin
-26.0%
PE vs Historical
-13.8 vs 45.3
CHEAP
Share & Embed Analysis
Last updated: July 14, 2026 10:21 PM ET
Data refreshes hourly during market hours. Next update: 11:21 PM
Data refreshes hourly during market hours. Next update: 11:21 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EVO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$198 | 58 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$116 | 59 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$110 | 58 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 58 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 54 HOLD |
